FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220960066> ?p ?o ?g. }

• W4220960066 endingPage "13" @default.
• W4220960066 startingPage "1" @default.
• W4220960066 abstract "Background. Soft-tissue sarcomas (STS) constitute a rare group of heterogeneous mesenchymal tumours containing more than 100 histologic subtypes. Here, we investigate whether, and if so, to what extent, skeletal metastases affect the outcome of patients with advanced or metastatic disease. Materials and Methods. Selected patients participated in five clinical trials of EORTC-STBSG. Individuals were included if they started treatment with an active drug and had advanced/metastatic STS. The endpoints of interest were overall survival (OS) and progression-free survival (PFS). Univariate and multivariate pooled analyses (after correcting for 12 covariates) were employed with Kaplan–Meier and Cox regression to model the impact of bone metastasis at presentation per treatment line stratified by study. For the subset of patients with bone metastasis, the impact of another metastatic organ site was explored with multivariate Cox regression models. Results. 565 out of 1034 (54.6%) patients received first-line systemic treatment for locally advanced or metastatic disease. Bone metastases were present in 140 patients (77 first-line, 63 second-line or higher). The unadjusted difference in OS/PFS with or without bone metastasis was statistically significant only for first-line patients. For OS, the adjusted hazard ratios for bone metastasis presence were 1.33 (95%-CI: 0.99–1.78) and 1.11 (95%-CI: 0.81–1.52) for first-line/second-line or higher treated patients, respectively. Likewise, the adjusted hazard ratios for PFS were 1.31 (95%-CI: 1.00–1.73) and 1.07 (95%-CI: 0.80–1.43). Effects were not statistically significant, despite a trend in first-line patients for both endpoints. Subgroup analyses indicated bone and lymph node metastasis as the most detrimental combination for OS and bone and lung metastasis for PFS. Conclusions. Adult STS patients receiving palliative systemic therapy with bone metastasis carried an overall worse prognosis than STS patients without bone metastases. Skeletal metastasis was detrimental for both OS and PFS, independent of the treatment line. Findings may have implications for the management of these patients." @default.
• W4220960066 created "2022-04-03" @default.
• W4220960066 creator A5006474472 @default.
• W4220960066 creator A5025935523 @default.
• W4220960066 creator A5030930203 @default.
• W4220960066 creator A5047837719 @default.
• W4220960066 creator A5048179253 @default.
• W4220960066 creator A5053304892 @default.
• W4220960066 creator A5055163903 @default.
• W4220960066 creator A5060949051 @default.
• W4220960066 creator A5060963439 @default.
• W4220960066 creator A5061157288 @default.
• W4220960066 creator A5076043217 @default.
• W4220960066 creator A5091114658 @default.
• W4220960066 date "2022-04-01" @default.
• W4220960066 modified "2023-10-02" @default.
• W4220960066 title "Prognostic Significance of Bone Metastasis in Soft Tissue Sarcoma Patients Receiving Palliative Systemic Therapy: An Explorative, Retrospective Pooled Analysis of the EORTC-Soft Tissue and Bone Sarcoma Group (STBSG) Database" @default.
• W4220960066 cites W1561999767 @default.
• W4220960066 cites W1958403054 @default.
• W4220960066 cites W2003950027 @default.
• W4220960066 cites W2004244160 @default.
• W4220960066 cites W2019607817 @default.
• W4220960066 cites W2034660548 @default.
• W4220960066 cites W2043466872 @default.
• W4220960066 cites W2074123600 @default.
• W4220960066 cites W2095393203 @default.
• W4220960066 cites W2101776780 @default.
• W4220960066 cites W2107230638 @default.
• W4220960066 cites W2112169652 @default.
• W4220960066 cites W2115453020 @default.
• W4220960066 cites W2136344041 @default.
• W4220960066 cites W2142653935 @default.
• W4220960066 cites W2165252656 @default.
• W4220960066 cites W2576440140 @default.
• W4220960066 cites W2588681363 @default.
• W4220960066 cites W2625310182 @default.
• W4220960066 cites W2755559037 @default.
• W4220960066 cites W2789692552 @default.
• W4220960066 cites W2800567296 @default.
• W4220960066 cites W2808496766 @default.
• W4220960066 cites W2883868866 @default.
• W4220960066 cites W3015411213 @default.
• W4220960066 cites W3016202049 @default.
• W4220960066 cites W3021104551 @default.
• W4220960066 cites W3022116443 @default.
• W4220960066 cites W3041140794 @default.
• W4220960066 cites W3049766571 @default.
• W4220960066 cites W3147894994 @default.
• W4220960066 cites W4211038654 @default.
• W4220960066 cites W4293241248 @default.
• W4220960066 cites W772589830 @default.
• W4220960066 doi "https://doi.org/10.1155/2022/5815875" @default.
• W4220960066 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35401025" @default.
• W4220960066 hasPublicationYear "2022" @default.
• W4220960066 type Work @default.
• W4220960066 citedByCount "1" @default.
• W4220960066 countsByYear W42209600662023 @default.
• W4220960066 crossrefType "journal-article" @default.
• W4220960066 hasAuthorship W4220960066A5006474472 @default.
• W4220960066 hasAuthorship W4220960066A5025935523 @default.
• W4220960066 hasAuthorship W4220960066A5030930203 @default.
• W4220960066 hasAuthorship W4220960066A5047837719 @default.
• W4220960066 hasAuthorship W4220960066A5048179253 @default.
• W4220960066 hasAuthorship W4220960066A5053304892 @default.
• W4220960066 hasAuthorship W4220960066A5055163903 @default.
• W4220960066 hasAuthorship W4220960066A5060949051 @default.
• W4220960066 hasAuthorship W4220960066A5060963439 @default.
• W4220960066 hasAuthorship W4220960066A5061157288 @default.
• W4220960066 hasAuthorship W4220960066A5076043217 @default.
• W4220960066 hasAuthorship W4220960066A5091114658 @default.
• W4220960066 hasBestOaLocation W42209600661 @default.
• W4220960066 hasConcept C121608353 @default.
• W4220960066 hasConcept C126322002 @default.
• W4220960066 hasConcept C136948725 @default.
• W4220960066 hasConcept C141071460 @default.
• W4220960066 hasConcept C142724271 @default.
• W4220960066 hasConcept C143998085 @default.
• W4220960066 hasConcept C144301174 @default.
• W4220960066 hasConcept C207103383 @default.
• W4220960066 hasConcept C2777783956 @default.
• W4220960066 hasConcept C2778256501 @default.
• W4220960066 hasConcept C2778629024 @default.
• W4220960066 hasConcept C2779013556 @default.
• W4220960066 hasConcept C2909636867 @default.
• W4220960066 hasConcept C38180746 @default.
• W4220960066 hasConcept C44249647 @default.
• W4220960066 hasConcept C50382708 @default.
• W4220960066 hasConcept C71924100 @default.
• W4220960066 hasConceptScore W4220960066C121608353 @default.
• W4220960066 hasConceptScore W4220960066C126322002 @default.
• W4220960066 hasConceptScore W4220960066C136948725 @default.
• W4220960066 hasConceptScore W4220960066C141071460 @default.
• W4220960066 hasConceptScore W4220960066C142724271 @default.
• W4220960066 hasConceptScore W4220960066C143998085 @default.
• W4220960066 hasConceptScore W4220960066C144301174 @default.
• W4220960066 hasConceptScore W4220960066C207103383 @default.
• W4220960066 hasConceptScore W4220960066C2777783956 @default.
• W4220960066 hasConceptScore W4220960066C2778256501 @default.

• next